Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pioglitazone + glimepiride is a fixed-dose oral combination medication used to treat type 2 diabetes mellitus as an adjunct to diet and exercise. It contains two active ingredients: - Pioglitazone, a thiazolidinedione that increases insulin sensitivity in fat, muscle, and liver cells. - Glimepiride, a sulfonylurea that stimulates the pancreas to release more insulin. This combination is indicated for adults with type 2 diabetes who are already treated with both drug classes or have inadequate glycemic control on either agent alone. It is not effective for type 1 diabetes or diabetic ketoacidosis. The most common side effects include upper respiratory tract infections, hypoesthesia (reduced sense of touch), bone fractures, weight gain, dizziness, flatulence (gas), and edema (swelling)[1][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pioglitazone + glimepiride.